文献速递骨质疏松与钙磷/甲状旁腺

家族性与多腺体原发性甲状旁腺功能亢进症中的GCM2变异

GCM2 Variants in Familial and Multiglandular Primary Hyperparathyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究对107例散发性多腺体或疑似/确诊家族性甲状旁腺肿瘤患者进行GCM2胚系变异测序,发现9例(8.4%)携带Y282D或Y394S变异;这些变异在患者中富集但外显率极低,其临床效用有待进一步研究。

要点

  • 107例散发性多腺体或家族性甲状旁腺肿瘤患者中,9例(8.4%)检出GCM2变异。
  • Y282D在多腺体病中富集5.9倍,外显率仅0.02%。
  • Y394S在散发性多腺体病和家族性PHPT中分别富集79倍和93倍,外显率低(1.33%和1.04%)。

核心结论

  • 在散发性多腺体或家族性甲状旁腺肿瘤患者中,体外激活型GCM2变异等位基因显著富集,但外显率极低,人群中多数携带者发生PHPT风险很低。
  • 检测这些GCM2变异的潜在临床效用需进一步研究,包括评估其作为致病/低外显率等位基因的可能作用。

研究设计与样本

  • 对107例散发性多腺体或疑似/确诊家族性甲状旁腺肿瘤患者的DNA进行PCR扩增和测序,检测PHPT相关GCM2胚系变异。

主要发现

  • 107例中9例(8.4%)检出GCM2变异:Y282D见于4例(6.3%)散发性多腺体病患者;Y394S见于2例(11.1%)家族性PHPT患者和3例(4.8%)散发性多腺体病患者。
  • 与一般人群相比,Y282D在多腺体病中富集5.9倍,外显率为0.02%。
  • Y394S在散发性多腺体病中富集79倍,在家族性PHPT中富集93倍,外显率分别为1.33%和1.04%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Multiglandular and familial parathyroid disease constitute important fractions of primary hyperparathyroidism (PHPT). Germline missense variants of GCM2, a regulator of parathyroid development, were observed in familial isolated hyperparathyroidism and sporadic PHPT. However, as these previously reported GCM2 variants occur at relatively high frequencies in the population, understanding their potential clinical utility will require both additional penetrance data and functional evidence relevant to tumorigenicity. OBJECTIVE: Determine the frequency of GCM2 variants of interest among patients with sporadic multigland or familial parathyroid disease and assess their penetrance. DESIGN AND PATIENTS: DNA-encoding PHPT-associated GCM2 germline variants were polymerase chain reaction-amplified and sequenced from 107 patients with either sporadic multigland or suspected/confirmed familial parathyroid tumors. RESULTS: GCM2 variants were observed in 9 of 107 cases (8.4%): Y282D in 4 patients (6.3%) with sporadic multigland disease; Y394S in 2 patients (11.1%) with familial PHPT and 3 (4.8%) with sporadic multigland disease. Compared with the general population, Y282D was enriched 5.9-fold in multigland disease, but its penetrance was very low (0.02%). Y394S was enriched 79-fold in sporadic multigland disease and 93-fold in familial PHPT, but its penetrance was low (1.33% and 1.04%, respectively). CONCLUSIONS: Observed in vitro-activating GCM2 variant alleles are significantly overrepresented in PHPT patients with multiglandular or familial disease compared to the general population, yet penetrance values are very low; that is, most individuals with these variants in the population have a very low risk of developing PHPT. The potential clinical utility of detecting these GCM2 variants requires further investigation, including assessing their possible role as pathogenic/low-penetrance alleles.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Vincze S, Peters NV, Kuo CL, et al. GCM2 Variants in Familial and Multiglandular Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2022. PMID: 34967908. doi:10.1210/clinem/dgab929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。